Innovation in The Clinic

Innovation reaching the clinic in 2015 thanks to MUSC Health clinician/researchers includes new drugs for heart failure and cystic fibrosis; new medical devices such as the first MRI-safe implantable cardioverter-defibrillator and a novel spinal surgery rod; and a diagnostic tool that will remove the ambiguity from lung cancer diagnosis. Clinical trials at MUSC Health are setting the standards for care nationwide and offering patients in the region access to revolutionary cancer treatments, including precision therapy and immunotherapy, as well as novel treatments for many other diseases, such as a thermosensitive gel for Menière’s disease, and a gene therapy for sickle cell disease. New centers are fostering a culture of innovation and helping translate that innovation into improved patient care.

New Options for Heart Failure

The summer of 2015 saw approval of the first new drug for heart failure (HF) in almost two decades.

Read More

Next Generation Devices

MUSC Health cardiologist Michael Gold, MD, has been key in introducing implantable cardioverter-defibrillator innovations.

Read More

Stroke Care

MUSC Health’s Division of Neuroendovascular Surgery has earned an international reputation for advancing intra-arterial therapies for ischemic stroke.

Read More

Advances for Healthy Lungs

Clinical trials conducted at MUSC and other sites that studied the efficacy of therapies for cystic fibrosis (CF) have revealed a winning two-drug combination.

Read More

Preventing Pulmonary Embolism

MUSC was awarded $13.5 million by the Patient-Centered Outcomes Research Institute (PCORI) to conduct a 25-site trial.

Read More
Innovation Cycle at MUSC

Culture of Innovation

Innovation is an essential survival tool for medical institutions as models of care and reimbursement undergo rapid change.

Read More
Medical oncologist Dr. John Wrangle leads trials of novel precision and immune-based therapeutics.

Cancer Therapy

In 2015, MUSC Hollings Cancer Center offered chances for patients to enter trials of two revolutionary approaches to cancer care.

Read More
Dr. Paul Lambert examining patient.

Groundbreaking Clinical Trials

An investigational treatment for Menière’s disease has shown safety & efficacy in phase 1b and 2b trials led by Paul R. Lambert, MD.

Read More